Spotlight
Video

TAK-931 - A CDC7 Inhibitor in Solid Tumors | Dosage Collision Study Shows Treatment is Tolerable

Loading........
Description: Ana Limon Carrera, Takeda Oncology, shares TAK-931 - A CDC7 Inhibitor in Solid Tumors | Dosage Collision Study Shows Treatment is Tolerable at Annual Meeting 2018
Shared By : Annual-Meeting
Posted on : 06/14/18
Added : 1 year ago



Recommended

Nothing found.